Preliminary Program Schedule & Invited Speakers

8th Annual SUO Meeting to Discuss Current Topics and Strategies
Co-Sponsored by: Society of Urologic Oncology/National Cancer Institute

November 29 – December 1, 2007
Natcher Conference Center
National Institutes of Health
Bethesda, Maryland

(Not all speakers have been confirmed and are subject to change)

THURSDAY, NOVEMBER 29, 2007 – Hyatt Regency Bethesda

2:00 p.m. – 5:30 p.m.  Registration

3:00 p.m. – 6:00 p.m.  Office-Based Pharmacologic Interventions for the Cancer Patient: A Primer for the Surgical Uro-Oncologist

6:00 p.m. – 9:30 p.m.  Young Urologic Oncologist (Y.U.O.) Program

6:30 p.m. – 7:00 p.m.  Update on SUO Long-Range Planning Activities
Speaker: Paul Lange, MD, University of Washington

7:00 p.m. – 7:30 p.m.  Young Urologic Oncologists (Y.U.O.) Investigator Award Presentation
Adam S. Kibel, MD, Washington University Medical School
Kenneth S. Koeneman, MD, University of Minnesota Medical School
David Ornstein, MD, University of California Irvine Medical Center

7:30 p.m. – 8:45 p.m.  Young Urologic Oncologists (Y.U.O.) Podium Presentations
Moderator: Jonathan Coleman, MD, Memorial Sloan Kettering Cancer Center

8:45 p.m. – 9:30 p.m.  Y.U.O. Business Meeting
FRIDAY, NOVEMBER 30, 2007 – Natcher Conference Center, National Institutes of Health

7:00 a.m. – 6:00 p.m. Registration

7:00 a.m. – 8:00 a.m. Continental Breakfast

8:00 a.m. – 8:05 a.m. Introduction
Ralph de Vere White, MD, President, Society of Urologic Oncology
W. Marston Linehan, MD, Past President, SUO and Program Co-Director

8:05 a.m. – 9:05 a.m. Bladder Cancer I: Nonmuscle Invasive Bladder — Evidence-Based Medicine
Moderator: Michael S. Cookson, MD, Vanderbilt University Medical Center

8:05 a.m. – 8:08 a.m. Introduction and Overview
Michael S. Cookson, MD, Vanderbilt University Medical Center

8:08 a.m. – 8:15 a.m. AUA Guidelines
John D. Seigne, MD, Dartmouth Hitchcock Medical Center

8:15 a.m. – 8:23 a.m. SIU Guidelines
Mark S. Soloway, MD, University of Miami School of Medicine

8:23 a.m. – 8:31 a.m. EAU Guidelines
J. A. Witjes, MD, Radboud University Nijmegen Medical Center

8:31 a.m. – 8:40 a.m. Understanding Guideline Methodology: Critical Analysis
Philipp Dahm, MD, University of Florida College of Medicine

8:40 a.m. – 9:05 a.m. Panel Discussion
Michael S. Cookson, MD
Mark S. Soloway, MD
J. A. Witjes, MD
Philipp Dahm, MD

9:05 a.m. – 10:05 a.m. Prostate Cancer I: Progress in Biomarkers
Moderator: Judd Moul, MD, Duke University

9:05 a.m. – 9:17 a.m. EPA2
Robert Getzenberg, PhD, Johns Hopkins

9:17 a.m. – 9:29 a.m. ETS-Fusion Proteins
Mark Rubin, MD, Brigham & Women’s Hospital

9:29 a.m. – 9:41 a.m. PSA as a Surrogate Endpoint
Dan Petrylak, MD, Columbia University

9:41 a.m. – 10:05 a.m. Panel Discussion
Judd Moul, MD
Robert Getzenberg, PhD
Mark Rubin, MD
Dan Petrylak, MD

10:05 a.m. – 10:20 a.m. Break

10:20 a.m. – 10:35 a.m. State-of-the-Art Talk: Recent Developments in the Treatment of Advanced Kidney Cancer
Ronald Bukowski, MD, Cleveland Clinic

10:35 a.m. – 11:00 a.m. Testis Cancer Update
Joel Scheinfeld, MD, Memorial Sloan Kettering Cancer Center

11:00 a.m. – 12:00 p.m. Kidney Cancer I: Management of Metastatic Disease
Moderator: Brian Rini, MD, Cleveland Clinic

11:00 a.m. – 11:05 a.m. DEBATE: Upfront Cytoreductive Nephrectomy
Pro: Upfront Cytoreductive Nephrectomy
Gerald Mickisch, MD, Center of Operative Urology Bremen

11:05 a.m. – 11:10 a.m. Con: Upfront Cytoreductive Nephrectomy
Christopher Wood, MD, M.D. Anderson Cancer Center

11:10 a.m. – 11:20 a.m. Choosing Appropriate Systemic Therapy
IL-2/Bevacizumab
James Yang, MD, National Cancer Institute

11:20 a.m. – 11:30 a.m. TKI’s
Michael Atkins, MD, Beth Israel Deaconess Medical Center

11:30 a.m. – 11:40 a.m. Systemic Therapy Sequences and Combinations That Make Sense
Brian Rini, MD, Cleveland Clinic

11:40 a.m. – 12:00 p.m. Panel Discussion
Brian Rini, MD
Gerald Mickisch, MD
Christopher Wood, MD
James Yang, MD
Michael Atkins, MD

12:00 p.m. – 1:30 p.m. Lunch

1:30 p.m. – 2:00 p.m. TBA

2:00 p.m. – 3:00 p.m. Prostate Cancer II: HRQOL and Prostate Cancer Treatment
Moderator: David Penson, MD, University of Washington

2:00 p.m. – 2:12 p.m. Results of the PROS-QA Study
Martin Sanda, MD, Beth Israel

2:12 p.m. – 2:34 p.m. Lessons from the Prostate Cancer Outcomes Study
David Penson, MD, University of Washington

2:34 p.m. – 2:46 p.m. Impact of Androgen Deprivation Therapy on the Health of Prostate Cancer Survivors
Matthew Smith, MD, Harvard

2:46 p.m. – 3:00 p.m. Panel Discussion
David Penson, MD
Martin Sanda, MD
Matthew Smith, MD
3:00 p.m. – 4:00 p.m.  
**Bladder Cancer II: Optimal Surgical Management of Invasive Bladder Cancer**  
Moderator: Bernard Bochner, MD, Memorial Sloan Kettering Cancer Center

**DEBATE: Open vs. MIS Approaches**  
Surgical Standards for Radical Cystectomy  
Bernard Bochner, MD, Memorial Sloan Kettering Cancer Center

3:05 p.m. – 3:15 p.m.  
**Open Radical Cystectomy**  
Eila Skinner, MD, Keck USC School of Medicine

3:15 p.m. – 3:25 p.m.  
**MIS Radical Cystectomy**  
Inderbir Gill, MD, Cleveland Clinic

3:25 p.m. – 3:27 p.m.  
**Rebuttal Open Cystectomy**  
Eila Skinner, MD, Keck USC School of Medicine

3:27 p.m. – 3:29 p.m.  
**Rebuttal MIS Cystectomy**  
Inderbir Gill, MD, Cleveland Clinic

3:29 p.m. – 4:00 p.m.  
**Panel Discussion**  
Bernard Bochner, MD  
Eila Skinner, MD  
Inderbir Gill, MD

4:00 p.m. – 6:00 p.m.  
**Poster Session/Reception**

7:00 p.m. – 7:30 p.m.  
**SUO Reception at Hyatt Regency Bethesda**

7:30 p.m.  
**SUO Dinner at Hyatt Regency Bethesda**

7:30 a.m. – 1:00 p.m.  
**Registration**

7:45 a.m. – 8:20 a.m.  
**Continental Breakfast**

8:20 a.m. – 8:50 a.m.  
**Young Urologic Oncologists (Y.U.O.)**  
Moderator: Jonathan Coleman, MD, Memorial Sloan Kettering Cancer Center

8:20 a.m. – 8:30 a.m.  
**Y.U.O. Abstract Presentation**

8:30 a.m. – 8:40 a.m.  
**Y.U.O. Abstract Presentation**

8:40 a.m. – 8:50 a.m.  
**Y.U.O. Abstract Presentation**

8:50 a.m. – 9:00 a.m.  
**Fellow/Resident Poster Session Awards**  
Introduction: John Lynch, MD, Georgetown University Medical Center  
Presentations: Jonathan Coleman, MD, Memorial Sloan Kettering Cancer Center

9:00 a.m. – 10:00 a.m.  
**Kidney Cancer II: Incidental Renal Mass — What is the Best Form of Management?**  
Moderator: Michael L. Blute, MD, Mayo Clinic (invited)

9:00 a.m. – 9:10 a.m.  
**Observation**  
Michael Jewett, MD, University of Toronto

9:10 a.m. – 9:20 a.m.  
**Ablation**  
Thomas Jarrett, MD, George Washington University Medical Center

9:20 a.m. – 9:30 a.m.  
**Open Partial Nephrectomy**  
Paul Russo, MD, Memorial Sloan Kettering Cancer Center (invited)

9:30 a.m. – 9:40 a.m.  
**Minimally-Invasive Partial Nephrectomy**  
Peter Pinto, MD, National Cancer Institute

9:40 a.m. – 10:00 a.m.  
**Panel Discussion**  
Michael L. Blute, MD  
Michael Jewett, MD  
Thomas Jarrett, MD  
Paul Russo, MD  
Peter Pinto, MD

10:00 a.m. – 10:15 a.m.  
**Break**

10:15 a.m. – 10:30 a.m.  
**Androgen Receptor Binding**  
David Neal, MD, Oxford

10:30 a.m. – 11:40 a.m.  
**Late Breaking Developments**  
Moderator: Ralph deVere White, MD, University of California Davis

11:40 a.m. – 12:20 p.m.  
**Prostate Cancer III: New Options for Hormone Refractory Disease**  
Moderator: Edward Messing, MD, University of Rochester

11:40 a.m. – 11:50 a.m.  
**Satraplatin**  
Oliver Sartor, MD, Dana Farber Cancer Institute

11:50 a.m. – 12:10 p.m.  
**Other Promising Agents**  
Dan Petrylak, MD, Columbia University

12:10 p.m. – 12:20 p.m.  
**Panel Discussion**  
Edward Messing, MD  
Oliver Sartor, MD  
Dan Petrylak, MD

12:20 p.m. – 1:00 p.m.  
**Bladder Cancer III: Controversies and Unmet Need in the Management of Upper Tract Transitional Cell Carcinoma**  
Moderator: Seth P. Lerner, MD, Baylor College of Medicine
12:20 p.m. – 12:23 p.m.  
Introduction and Overview  
Seth P. Lerner, MD,  
Baylor College of Medicine

12:23 p.m. – 12:35 p.m.  
Principles of Nephroureterectomy and 
RPLND — Lap vs Open  
Thomas Jarrett, MD,  
George Washington University  
Medical Center  
Michael Jewett, MD,  
University of Toronto

12:35 p.m. – 12:43 p.m.  
Rationale for Integration of Systemic 
Chemotherapy and Surgery  
Walter Stadler, MD,  
University of Chicago

12:43 p.m. – 1:00 p.m.  
Panel Discussion  
Seth P. Lerner, MD  
Thomas Jarrett, MD  
Michael Jewett, MD  
Walter Stadler, MD

1:00 p.m.  
Adjourn

General Information

The 8th annual scientific meeting on urologic oncology will be held November 29 – December 1, 2007 at the Natcher Conference Center on the campus of the National Institutes of Health. The Society of Urologic Oncology and the National Cancer Institute’s Urologic Oncology Program will jointly sponsor this interactive meeting where all attendees participate in the discussions. State-of-the-art topics on prostate, kidney and bladder cancer, as well as strategies in urologic oncology, will be discussed.

The goal of this meeting is to increase communication among urologic oncology researchers and forge a strong relationship between the National Cancer Institute and the Society of Urologic Oncology, as well as the Society’s members and others interested in urologic oncology.

Who Should Attend

- Urological surgeons
- Medical oncologists
- Radiation oncologists
- Research scientists
- Residents/fellows-in-training

Attendee Participation

This meeting is designed to be a discussion of issues among members of the urologic oncology community at the National Institutes of Health. All attendees participate in the discussions and, depending on the session, may present up to two slides.